Crossmark Global Holdings Inc. boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 32.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 53,438 shares of the company's stock after buying an additional 12,956 shares during the period. Crossmark Global Holdings Inc.'s holdings in AstraZeneca were worth $4,164,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its holdings in shares of AstraZeneca by 17.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company's stock valued at $4,151,177,000 after purchasing an additional 9,002,450 shares during the period. Swedbank AB acquired a new position in shares of AstraZeneca in the 1st quarter valued at about $186,127,000. Manning & Napier Advisors LLC acquired a new position in shares of AstraZeneca in the 2nd quarter valued at about $188,476,000. Hsbc Holdings PLC increased its holdings in shares of AstraZeneca by 750.3% in the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company's stock valued at $100,523,000 after purchasing an additional 1,132,362 shares during the period. Finally, Farallon Capital Management LLC increased its holdings in shares of AstraZeneca by 65.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company's stock valued at $187,934,000 after purchasing an additional 950,000 shares during the period. Institutional investors and hedge funds own 20.35% of the company's stock.
A number of equities analysts have recently weighed in on AZN shares. TD Cowen upped their target price on AstraZeneca from $90.00 to $95.00 and gave the company a "buy" rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. Finally, Erste Group Bank raised AstraZeneca from a "hold" rating to a "buy" rating in a research note on Wednesday, September 11th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, AstraZeneca has a consensus rating of "Buy" and an average price target of $89.75.
View Our Latest Analysis on AZN
Shares of NASDAQ AZN opened at $64.79 on Tuesday. The stock has a market cap of $200.89 billion, a price-to-earnings ratio of 31.30, a PEG ratio of 1.19 and a beta of 0.47. The business has a 50 day simple moving average of $76.61 and a 200 day simple moving average of $78.54. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.